| In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng W Wang, Y Zhao, ER Rayburn, DL Hill, H Wang, R Zhang Cancer chemotherapy and pharmacology 59, 589-601, 2007 | 396 | 2007 |
| Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action SA Nag, JJ Qin, W Wang, MH Wang, H Wang, R Zhang Frontiers in pharmacology 3, 25, 2012 | 352 | 2012 |
| Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function D Chen, Z Zhang, M Li, W Wang, Y Li, ER Rayburn, DL Hill, H Wang, ... Oncogene 26 (35), 5029-5037, 2007 | 315 | 2007 |
| Targeting the NFκB signaling pathways for breast cancer prevention and therapy W Wang, SA Nag, R Zhang Current medicinal chemistry 22 (2), 264-289, 2015 | 233 | 2015 |
| Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications W Wang, S Nag, X Zhang, MH Wang, H Wang, J Zhou, R Zhang Medicinal research reviews 35 (2), 225-285, 2015 | 211 | 2015 |
| Molecular targeting therapies for neuroblastoma: Progress and challenges A Zafar, W Wang, G Liu, X Wang, W Xian, F McKeon, J Foster, J Zhou, ... Medicinal research reviews 41 (2), 961-1021, 2021 | 210 | 2021 |
| Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis EC LaCasse, GG Cherton-Horvat, KE Hewitt, LJ Jerome, SJ Morris, ... Clinical cancer research 12 (17), 5231-5241, 2006 | 180 | 2006 |
| NFAT as cancer target: mission possible? JJ Qin, S Nag, W Wang, J Zhou, WD Zhang, H Wang, R Zhang Biochimica Et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 297-311, 2014 | 151 | 2014 |
| Targeting MDM2-p53 interaction for cancer therapy: are we there yet? S Nag, X Zhang, KS Srivenugopal, MH Wang, W Wang, R Zhang Current medicinal chemistry 21 (5), 553-574, 2014 | 142 | 2014 |
| 20 (S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action W Wang, H Wang, ER Rayburn, Y Zhao, DL Hill, R Zhang British journal of cancer 98 (4), 792-802, 2008 | 142 | 2008 |
| Polycomb group (PcG) proteins and human cancers: multifaceted functions and therapeutic implications W Wang, JJ Qin, S Voruganti, S Nag, J Zhou, R Zhang Medicinal research reviews 35 (6), 1220-1267, 2015 | 132 | 2015 |
| Experimental therapy of prostate cancer with novel natural product anti‐cancer ginsenosides W Wang, ER Rayburn, M Hao, Y Zhao, DL Hill, R Zhang, H Wang The Prostate 68 (8), 809-819, 2008 | 132 | 2008 |
| Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action W Wang, ER Rayburn, Y Zhao, H Wang, R Zhang Cancer letters 278 (2), 241-248, 2009 | 117 | 2009 |
| Morphology and Amine Accessibility of (3‐Aminopropyl) Triethoxysilane Films on Glass Surfaces W Wang, MW Vaughn Scanning: The Journal of Scanning Microscopies 30 (2), 65-77, 2008 | 109 | 2008 |
| Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2 W Wang, X Zhang, JJ Qin, S Voruganti, SA Nag, MH Wang, H Wang, ... PLoS One 7 (7), e41586, 2012 | 96 | 2012 |
| Isolation, structural determination, and evaluation of the biological activity of 20 (S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20 (S)-25-OCH3-PPD], a novel natural product … Y Zhao, W Wang, L Han, ER Rayburn, DL Hil, H Wang, R Zhang Medicinal Chemistry 3 (1), 51-60, 2007 | 94 | 2007 |
| The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models W Wang, JJ Qin, S Voruganti, KS Srivenugopal, S Nag, S Patil, H Sharma, ... Nature communications 5 (1), 5086, 2014 | 92 | 2014 |
| Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop X Zhang, W Wang, H Wang, MH Wang, W Xu, R Zhang Oncogene 32 (22), 2782-2791, 2013 | 92 | 2013 |
| Natural products targeting the p53-MDM2 pathway and mutant p53: recent advances and implications in cancer medicine JJ Qin, X Li, C Hunt, W Wang, H Wang, R Zhang Genes & diseases 5 (3), 204-219, 2018 | 90 | 2018 |
| Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP S Yin, S Kaluz, NS Devi, AA Jabbar, RG de Noronha, J Mun, Z Zhang, ... Clinical Cancer Research 18 (24), 6623-6633, 2012 | 88 | 2012 |
Ruiwen ZhangProfessor of Pharmacology and Toxicology, Robert L. Boblitt Endowed Professor in Drug DiscoveryVerified email at central.uh.edu
